Back to today’s briefing

Story perspectives

Heart Patients Demand Funding Amid Health Care Struggles

10/2/2025

25 4 Full Breakdown

Summary

Story summary

Thousands of New Zealand heart patients with familial hypercholesterolaemia lack Pharmac funding for PCSK9 inhibitors.
Kia Manawanui Trust stresses need for these medications; heart disease remains the leading cause of death.
In Auckland, families are urged to keep children up to date with immunisations.
A family faced Air New Zealand abroad, criticizing rigid rebooking policies and lack of empathy.

History

Historical Context

Since the 1980s, New Zealand's healthcare system has shifted from a fully public model to a mixed public-private system, impacting funding for essential medications. In 2016, Pharmac allocated only 1.5% of its budget to new medicines, affecting access to treatments like PCSK9 inhibitors for heart patients. This ongoing issue highlights the need for systemic reforms to address healthcare disparities.

1 of 2

Story summary

Thousands of New Zealand heart patients with familial hypercholesterolaemia lack Pharmac funding for PCSK9 inhibitors.
Kia Manawanui Trust stresses need for these medications; heart disease remains the leading cause of death.
In Auckland, families are urged to keep children up to date with immunisations.
A family faced Air New Zealand abroad, criticizing rigid rebooking policies and lack of empathy.

1 / 2